McVean, a former pediatric endocrinologist for the University of Minnesota Physicians and an associate professor in the pediatrics department at the University of Minnesota Medical School, will take up a role aimed at augmenting Medtronic’s commitment to providing a full product portfolio and education and support tools to make living with diabetes easier for pediatric patients and their families.
Her official role will be Medical Affairs Director for the diabetes business at Medtronic.
“We are excited to welcome Dr. McVean to our Medtronic team as she brings in a wealth of experiences and insights that are informed by her personal diabetes journey,” CMO of Medtronic’s diabetes business Dr. Robert Vigersky said in a news release. “Her compassionate approach to diabetes management and deep commitment to serving the community were a perfect match with our mission-driven culture and patient-first mindset.
“Dr. McVean has a wonderful reputation in the clinical and patient communities and we’re all looking forward to benefiting from her close partnership as we look to serve even more patients around the world with technologies that provide greater freedom and better health.”
McVean will offer medical expertise and strategic guidance based on her pediatric endocrinology background, providing viewpoints on regulatory strategy, evidence development, product design, clinical communications and publications, marketing nad commercial strategies and training and support needs, Medtronic said.
Her efforts to accelerate innovation in diabetes management is born out of the fact that she herself has lived with the disease as well.
“I’ve seen how advancements in diabetes technology can improve outcomes and decrease burden for my patients and their families and for me as a long-time Medtronic insulin pump user,” said McVean, M.D., medical affairs director of the Diabetes business at Medtronic. “As a pediatric endocrinologist and a person who has lived with type 1 diabetes for 34 years, I am intimately aware of the unrelenting challenges of day-to-day management and significant mental burden of this disease on children and their caregivers, adolescents and adults. Medtronic technologies currently deliver positive clinical outcomes; and with sharp and increased focus on ease of use and overall user experience, there is tremendous opportunity ahead to make these comprehensive offerings even better.”
McVean joins Medtronic as it plans to make major regulatory steps for its next-generation insulin pump and sensor during this fiscal year.
In October, the company reported positive one-year, real-world clinical data for the next-generation MiniMed 780G insulin pump platform in pediatric patients as well.
